CLL Prognostication/Risk Stratification Gene Panel

Also referred as

Chronic Lymphocytic Leukaemia Genetic Testing

For men & women

Earliest reports in

432 hours

Contains

1 test

Test price:

₹19950

~~₹21000~~

5% off

Know more about this test

The CLL Prognostication/Risk Stratification Gene Panel is an advanced genetic test that helps predict how Chronic Lymphocytic Leukemia (CLL) is likely to progress. It detects specific gene mutations linked to disease behavior, treatment response, and overall prognosis. This information helps doctors personalize treatment and make better-informed decisions for managing CLL.

Samples required

Blood

Find out

Why is this test booked?

Preparation for this test

Sample Collection

Who will collect your samples?

Test conducted by

Core Diagnostics Private Limited

ISO, CAP, NABL certified

Know More

Know more about lab

Core Diagnostics Private Limited

ISO, CAP, NABL certified

About this lab

We at CORE Diagnostics are a renowned pathology testing laboratory & a premier institute in the country capable of providing varied diagnostic tests & facilities in the field of laboratory medicine and have established state-of-art testing facilities in Gurgaon. We are a Clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection. We are focused on bringing the most advanced testing techniques and expertise to India and aim to become the destination for all your high-end diagnostic needs.

Understanding CLL Prognostication/Risk Stratification Gene Panel

The CLL Prognostication/Risk Stratification Gene Panel is a Next-Generation Sequencing (NGS)–based molecular test performed on EDTA whole blood samples. It analyzes key genes and mutations linked with the development and behavior of Chronic Lymphocytic Leukemia (CLL), a cancer of the blood and bone marrow that affects white blood cells.

CLL is a heterogeneous disease, meaning it behaves differently in every patient. Some cases progress slowly and require only monitoring, while others are more aggressive and need early intervention. This gene panel helps doctors assess an individual’s risk level and make informed clinical decisions.

The test evaluates mutations in important hotspot, full, and fusion genes associated with CLL and other hematological malignancies:

Hotspot genes: ABL1, FLT3, JAK2, MYD88, SF3B1
Full genes: SH2B3, TP53
Gene fusions: FGFR1, FGFR2, PDGFRA, PDGFRB

By detecting these gene mutations, the test helps doctors stratify patients into risk categories (low, intermediate, or high risk) and decide on the most suitable treatment approach, whether active monitoring, targeted therapy, or clinical trial enrollment.

Doctors may recommend this test for individuals with newly diagnosed CLL, persistent or relapsed disease, or those who show clinical signs of disease progression such as rapid lymphocyte doubling, cytopenias, or organ enlargement.

For this test, it is important to submit the clinical history, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled.

Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for a proper understanding of the test results.

What does CLL Prognostication/Risk Stratification Gene Panel measure?

The CLL Prognostication/Risk Stratification Gene Panel analyzes multiple genes in the blood that are linked to the development and progression of Chronic Lymphocytic Leukemia (CLL). It uses advanced PCR-based next-generation sequencing (NGS) to detect genetic mutations and variations that help predict how aggressive the disease might be and how it may respond to treatment.

This panel includes:

Hotspot genes (ABL1, FLT3, JAK2, MYD88, SF3B1): Common regions where mutations often occur in blood cancers.

Full genes (SH2B3, TP53): Entire genes analyzed to identify both common and rare mutations that influence prognosis and therapy response.

Gene fusions (FGFR1, FGFR2, PDGFRA, PDGFRB): Abnormal joining of genes that may drive cancer growth and affect targeted treatment choices.

By studying these genes, the test helps determine disease prognosis, identify high-risk patients, and guide doctors in planning personalized treatment strategies and follow-up care.

Test Information is reviewed by: Dr. Swati Gupta (Anand), MD Lab Medicine, MBBS and written by Shweta Prakash, MSc, BSc . The test details are for information purpose only. Consult a doctor before taking any test. Last updated on: 15th Aug 2026

Did you find information useful ?

YES

CLL Prognostication/Risk Stratification Gene Panel test price for other cities

Price in	Ahmedabad	Rs. 19950
Price in	Allahabad	Rs. 19950
Price in	Asansol	Rs. 19950
Price in	Bangalore	Rs. 19950
Price in	Bhopal	Rs. 19950

Book a CLL Prognostication/Risk Stratification Gene Panel test at home near me

Easy online booking

Search for tests and packages, book your preferred time slot and enter your address for seamless at-home lab tests.

Live tracking of phlebotomist

Track our trained phlebotomist's real time location for seamless sample collection.

Safe Sample Collection

Our phlebotomists follow strict safety protocols to collect samples safely at home and on time.

Sample received at lab

Samples are transported securely to our accredited labs with world-class machines for testing by qualified experts.

Quick, Doctor-Verified Reports

Get doctor-approved reports via email and WhatsApp, with options for doctor follow-ups and AI insights.

FAQs related to CLL Prognostication/Risk Stratification Gene Panel

What is the CLL Prognostication/Risk Stratification Gene Panel?

It is a genetic test that uses Next-Generation Sequencing (NGS) to detect mutations and fusions in multiple genes associated with Chronic Lymphocytic Leukemia (CLL). The results help predict disease progression and guide personalized treatment.

Why is this test important?

CLL behaves differently in each patient. This test helps doctors understand the genetic profile of the disease, assess risk levels, and make evidence-based treatment decisions to improve long-term outcomes.

Who should get this test?

This test is recommended for individuals who: Have been newly diagnosed with CLL Show signs of disease progression or relapse Have unexplained low blood counts (cytopenias) or rapidly rising lymphocyte counts Need risk assessment before starting or changing therapy

How is the CLL Prognostication/Risk Stratification Gene Panel performed?

A phlebotomist will clean your skin using an antiseptic alcohol cotton swab or wipe and take blood samples from your vein using a needle. The blood sample will be stored safely and transported to the laboratory for analysis.

Do I need to fast before taking the CLL Prognostication/Risk Stratification Gene Panel?

No fasting is required for this test. You can schedule it at your convenience without avoiding food or water beforehand.

Is there any risk associated with the CLL Prognostication/Risk Stratification Gene Panel?

No, the CLL Prognostication/Risk Stratification Gene Panel is generally safe with minimal risks. However, you may feel slight discomfort during blood sample collection, but the chances of serious complications are extremely rare.

What do abnormal results mean?

Abnormal findings may indicate the presence of high-risk genetic mutations, suggesting that the CLL could progress faster or respond differently to treatment. Your doctor will interpret the results and plan a personalized treatment approach accordingly.

Can this test detect other types of cancer?

No, this panel is designed specifically for CLL-related mutations and does not detect other cancers.

Can this test be repeated?

Yes. Your doctor may recommend retesting if your disease relapses or before adjusting treatment plans.

Is this test safe for older adults?

Yes. Since CLL primarily affects older individuals, this test is safe and commonly used for elderly patients.

What is Chronic Lymphocytic Leukemia (CLL)?

Chronic Lymphocytic Leukemia (CLL) is a type of blood and bone marrow cancer that affects white blood cells called lymphocytes. These abnormal cells build up slowly over time, interfering with normal blood cell production and immune function.

Need help?